Article · Wikipedia archive · Last revised Jul 22, 2026

Vorolanib

Vorolanib is a drug with antiangiogenic and antineoplastic activities. In 2023, vorolanib was approved for use in China. It is used in combination with everolimus for the treatment of advanced renal cell carcinoma in patients who have previously received tyrosine kinase inhibitor treatment but failed.

Last revised
Jul 22, 2026
Read time
≈ 1 min
Length
276 w
Citations
5
Source
Wikipedia ↗
Vorolanib
Clinical data
Trade names伏美纳
Other namesCM082; CM-082
Legal status
Legal status
  • Rx in China
Identifiers
  • N-[(3S)-1-(Dimethylcarbamoyl)pyrrolidin-3-yl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
CAS Number
PubChem CID
DrugBank
UNII
ChEMBL
Chemical and physical data
FormulaC23H26FN5O3
Molar mass439.491 g·mol−1
3D model (JSmol)
  • CC1=C(NC(=C1C(=O)N[C@H]2CCN(C2)C(=O)N(C)C)C)/C=C\3/C4=C(C=CC(=C4)F)NC3=O
  • InChI=1S/C23H26FN5O3/c1-12-19(10-17-16-9-14(24)5-6-18(16)27-21(17)30)25-13(2)20(12)22(31)26-15-7-8-29(11-15)23(32)28(3)4/h5-6,9-10,15,25H,7-8,11H2,1-4H3,(H,26,31)(H,27,30)/b17-10-/t15-/m0/s1
  • Key:KMIOJWCYOHBUJS-HAKPAVFJSA-N

Vorolanib is a drug with antiangiogenic and antineoplastic activities.1 In 2023, vorolanib was approved for use in China. It is used in combination with everolimus for the treatment of advanced renal cell carcinoma in patients who have previously received tyrosine kinase inhibitor treatment but failed.2

Vorolanib is also being evaluated for the treatment of neovascular age‑related macular degeneration.3 and its azidated and chlorinated version, termed EYE1118, is designed to be targeted to the eye by natural light to reduce retinal and choroidal neovascularization locally.4

It is a dual inhibitor that targets both vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs).5

References

References

  1. Liang C, Yuan X, Shen Z, Wang Y, Ding L (March 2022). "Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity". Molecular Therapy Oncolytics. 24: 577–584. doi:10.1016/j.omto.2022.01.001. PMC 8861424. PMID 35252556.
  2. "Vorolanib Tablets Approved for Marketing by China NMPA". National Medical Products Administration. 2023-06-08.
  3. Walia S, Morya AK, Khullar S, Aggarwal S, Kaur R (August 2025). "Role of alternative oral therapy for the management of wet age-related macular degeneration and proliferative diabetic retinopathy". World Journal of Diabetes. 16 (8) 109231. doi:10.4239/wjd.v16.i8.109231. PMC 12362450. PMID 40837344.
  4. B. Besztercei, R. Antal, L. Tähtivaara, B. Lappeteläinen, N. Jääskeläinen, A. Szappanos, Á. Lukáts, A. Pál-Kajtár, A. Budai, M. Cerrada-Gimenez, K.A. Kovács (2026). "Three nitrogen atoms turn old kinase inhibitors into new targetable remedy". bioRxiv 10.64898/2026.04.11.717649.{{cite bioRxiv}}: CS1 maint: multiple names: authors list (link)
  5. "Vorolanib". NCI Drug Dictionary. National Cancer Institute.